

## Regulatory Announcement

**Company** Akers Biosciences, Inc.  
**TIDM** AKR  
**Headline** Director/PDMR Shareholding  
**Released** 16:42 25-Jul-07  
**Number** 8732A

### **Akers Biosciences, Inc.** ("ABI" or the "Company")

#### **Employee Shareholding & Additional Listing**

Akers Biosciences, Inc. which develops, manufactures, and supplies rapid, point of care screening and testing products announces that Company employees have, on 24 July 2007, increased their shareholdings in the Company by way of a subscription to New Ordinary shares.

Patrice McMorrow, Director of Marketing, has invested \$4,715 by way of a subscription to 20,000 New Ordinary Shares at yesterday's closing price of 11.50 pence. Ms. McMorrow's shareholdings now total 20,000 common shares, representing less than .001% of the total issued share capital of the Company.

Anna Marie Arzillo, Assistant Corporate Secretary, has invested \$4,715 by way of a subscription to 20,000 New Ordinary Shares at yesterday's closing price of 11.50 pence. Ms. Arzillo's shareholdings now total 20,000 common shares, representing less than .001% of the total issued share capital of the Company.

Barbara A. Bagby, Director of Regulatory Affairs, has invested \$4,715 by way of a subscription to 20,000 New Ordinary Shares at yesterday's closing price of 11.50 pence. Ms. Bagby's shareholdings now total 20,000 common shares, representing less than .001% of the total issued share capital of the Company.

Robert J. Paratore, Financial Controller, has invested \$2,357 by way of a subscription to 10,000 New Ordinary Shares at yesterday's closing price of 11.50 pence. Mr. Paratore's shareholdings now total 10,000 common shares, representing less than .001% of the total issued share capital of the Company.

Carl E. King, Director BreathScan Division, has invested \$2,357 by way of a subscription to 10,000 New Ordinary Shares at yesterday's closing price of 11.50 pence. Mr. King's shareholdings now total 10,000 common shares, representing less than .001% of the total issued share capital of the Company.

Application has been made to the London Stock Exchange for 80,000 New Ordinary Shares, which will rank pari passu with existing Ordinary Shares, to be admitted to trading, such admission expected to take place on 1 August 2007.

The exchange rate used for these transactions was \$2.05:£1.00.

#### **Enquiries:**

Thomas A. Nicolette, President & CFO  
Akers Biosciences, Inc.  
Tel. 001 856 848 8698

Ben Simons  
Hansard Group  
Tel. 020 7245 1100

END